Bayer: heart drug meets primary endpoint
(CercleFinance.com) - A trial of Bayer and Merck's experimental drug vericiguat found that it reduced the risk of cardiovascular death or heart failure hospitalization versus placebo, Bayer said on Monday.
The Phase 3 trial - which enrolled 5,050 patients - met its primary endpoint by showing superiority in prolonging the time to first occurrence of the composite endpoint of cardiovascular death or heart failure hospitalization in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF), Bayer said.
Bayer and Merck have been collaborating on soluble guanylate cyclase (sGC) modulators, an important function of blood vessels, since 2014.
Heart failure affects over 60 million people worldwide each year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Phase 3 trial - which enrolled 5,050 patients - met its primary endpoint by showing superiority in prolonging the time to first occurrence of the composite endpoint of cardiovascular death or heart failure hospitalization in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF), Bayer said.
Bayer and Merck have been collaborating on soluble guanylate cyclase (sGC) modulators, an important function of blood vessels, since 2014.
Heart failure affects over 60 million people worldwide each year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.